Languages

Blog

First patient with refractory lupus nephritis treated with irinotecan
New publication in the Scandinavian Journal of Rheumatology     2021-11- 2

Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapy

New Research Funding for LUNIRI
2018-08-21

Steffen Frese, the founder of LUNIRI, received new research funding from the German Research Foundation. http://gepris.dfg.de/gepris/projekt/317392477?language=en Research will be conducted at the German Rheumatism Research Centre in Berlin, Germany.&nb ... Read More

Berlin Marathon 2017
Running for lupus. Running for the new treatment.     2017-09-27

LUNIRI in the News
Lupus Nephritis and Irinotecan at LUPUSNEWSTODAY.COM     2016-11-30

http://lupusnewstoday.com/2016/11/11/irinotecan-topo-1-blocker-seen-as-potential-lupus-specific-treatment

Neue Ergebnisse aus der Forschung veröffentlich in Arthritis Research & Therapy
Wir konnten zeigen, dass Irinotecan in einem zweiten Model von spontaner Lupuserkrankung sowohl die Nieren- als auch die Hautbeteiligung effektiv unterdrückt.     2016-10-25

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther. 2016 Oct 22; 18(1):243

New scientific data published in Arthritis Research & Therapy
Irinotecan efficiently suppressed both lupus nephritis and skin lesions in a second and genetically different model of spontaneous SLE     2016-10-25

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther. 2016 Oct 22; 18(1):243

More Blog Entries
Categories
Archives

Kontakt

LUNIRI Gemeinnützige GmbH
Hauptstraße 117
10827 Berlin, GERMANY

E-Mail: info(at)luniri.com